Genzyme - Wikipedia
WEBGenzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...
Eleven years after buying Genzyme, Sanofi officially ditches ...
WEBFeb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme â  just Sanofi, as part of a...
Sanofi Pharmaceuticals - Healthcare Innovations | Sanofi USA
WEBSep 11, 2024 · Discover how Sanofi, a global pharmaceutical company, is shaping healthcare in the US with innovative solutions and treatments.
Genzyme Corporation Company Information - Drugs.com
WEBAug 1, 2014 · Drug class: lysosomal enzymes. For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). Genzyme Corporation manufactures, markets and/or distributes more than 10 drugs in the U.S.
Genzyme Corporation -- Company History
WEBCompany History: Genzyme Corporation is a leading biotechnology company that focuses on five business areas: therapeutics, diagnostic services, diagnostic products, pharmaceutical and fine chemicals, and tissue repair.
Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR ...
WEBFeb 16, 2011 · Sanofi-aventis’ dogged pursuit of Genzyme has finally led to the boards of both firms agreeing to a $74 cash per share plus contingent value rights (CVRs) acquisition of the latter by the French...
Sanofi-Genzyme: Still successful 5 years after the acquisition
WEBBack in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi?
Sanofi buys Genzyme for $20.1bn - Financial Times
WEBFeb 16, 2011 · Sanofi-Aventis has ended a nine-month pursuit of US biotech company Genzyme with a $20.1bn deal worth $74 a share, Bloomberg says. The French drugmaker will now be able to add rare disease ...
Genzyme | Company Overview & News - Forbes
WEBGenzyme Corporation (Genzyme) is a biotechnology company. The Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer,...
Timeline: Sanofi's quest for U.S. biotech Genzyme | Reuters
WEBFeb 16, 2011 · PARIS (Reuters) - Sanofi-Aventis has reached an agreement in principle to acquire Genzyme Corp for about $19.2 billion in cash plus future payments based on the performance of an experimental ...